Related Experiment Video
Updated: Nov 9, 2025

06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
3.1K
[Progressive supranuclear paralysis with levodopa-induced dyskinesia].
Sh M Safin1, H P Derevyanko1, N M Blinova1
1Bashkir State Medical University, Ufa, Russia.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
|April 9, 2021
Summary
Progressive supranuclear palsy (PNP) is a rare neurodegenerative disease. This case study details a 79-year-old patient experiencing oromandibular hyperkinesis while treated with levodopa.
Area of Science:
- Neurology
- Neurodegenerative Diseases
Background:
- Progressive supranuclear palsy (PNP) is a rare, fatal neurodegenerative disease typically affecting individuals over 60.
- Characterized by akinetic-rigid syndrome, falls, supranuclear ophthalmoplegia, pseudobulbar symptoms, and frontal dementia.
Observation:
- A clinical case of a 79-year-old patient diagnosed with progressive supranuclear palsy is presented.
- The patient exhibited oromandibular hyperkinesis, an involuntary movement disorder affecting the jaw and mouth.
- This specific symptom occurred during levodopa treatment.
Findings:
- The case highlights a less commonly reported side effect of levodopa in PNP patients.
- Oromandibular hyperkinesis may manifest as a complex motor symptom in advanced stages of the disease.
- Detailed clinical description of this presentation is provided.
Implications:
- Understanding levodopa's potential side effects is crucial for managing PNP symptoms.
- This case contributes to the literature on atypical motor manifestations in progressive supranuclear palsy.
- Further research may explore the mechanisms linking levodopa to hyperkinesis in neurodegenerative conditions.
Related Concept Videos
Parkinson's Disease: Treatment
694
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
694
Parkinson's Disease: Overview
1.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.1K
Neural Regulation
41.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
41.1K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
840
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
840
Depolarizing Blockers: Pharmocokinetics
440
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
440
Depolarizing Blockers: Mechanism of Action
2.2K
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
2.2K

